7 terminated, 3 active not recruiting, 3 completed, 3 recruiting. 13 Phase 1, 8 Phase 2, 1 Early Phase 1.
Follow NeoImmuneTech: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel) NT-I7, Placebo - Multiple Myeloma, Multiple Myeloma in Relapse | Phase 1 | Recruiting | Washington University School of Medicine | 52 | 2026-06-05 | 2026-10-15 |
| NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma NT-I7, CAR T-cell therapy - Large B-cell Lymphoma | Phase 1 | Recruiting | Washington University School of Medicine | 24 | 2026-03-12 | 2026-09-29 |
| A Single-arm, Dose-escalation Trial of Long-acting Recombinant Human IL-7 (NT-I7, Efineptakin Alfa) for Idiopathic CD4 Lymphopenia Recombinant human interleukin (IL) 7-hyFc - Idiopathic CD4 Lymphopenia | Phase 1 / Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 60 | 2024-11-06 | 2026-10-19 |
| Vaccine Response With NT-I7 Recombinant human IL-7-hyFc (NT-I7), Vaccine sequence 1, Vaccine sequence 2 - Breast Carcinoma, Colorectal Adenocarcinoma | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2023-05-30 | 2023-11-02 | |
| Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma Biospecimen Collection, Efineptakin alfa, Pembrolizumab - High Grade Astrocytic Tumor, Recurrent Glioblastoma, IDH-Wildtype | Phase 2 | Active not recruiting | Mayo Clinic | 53 | 2023-01-24 | 2026-10-05 |
| Trial of the Combination of GX-188E Vaccination, GX-I7 and Pembrolizumab in Patients With Advanced, Resectable HPV Type 16 and/or 18 Positive Head and Neck Cancer GX-188E, GX-I7, Pembrolizumab, GX-188E, Pembrolizumab, GX-188E, GX-I7 - Head and Neck Squamous Cell Carcinoma | Phase 2 | Active not recruiting | Yonsei University | 56 | 2022-03-01 | 2026-02-09 |
| NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC efineptakin alfa, Atezolizumab - Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer | Phase 2 | Terminated | NeoImmuneTech | 33 | 2021-11-15 | 2026-06-11 |
| Evaluating the Effect of NT-I7, a Long Acting Interleukin-7, to Increase Lymphocyte Counts and Enhance Immune Clearance of SARS-CoV-2 (COVID-19) NT-I7, Placebo, Blood for research purposes - COVID-19, SARS-CoV-2 | Phase 1 | Withdrawn | Washington University School of Medicine | 2021-07-31 | 2021-08-05 | |
| Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy Efineptakin alfa, Tisagenlecleucel, Axicabtagene ciloleucel - Refractory Diffuse Large B-cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Completed | NeoImmuneTech | 17 | 2021-07-29 | 2026-08-10 |
| NT-I7, a Long-Acting Recombinant IL-7 Molecule, as an Immune Reconstitution Strategy for Lymphopenia in Patients With Progressive Multifocal Leukoencephalopathy NT-I7 - Progressive Multifocal Leukoencephalopathy | Early Phase 1 | Completed | National Institute of Neurological Disorders and Stroke (NINDS) | 12 | 2021-05-05 | 2025-11-18 |
| NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery Efineptakin alfa - Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma | Phase 1 | Terminated | Hyunseok Kang, MD | 4 | 2021-03-12 | 2025-02-14 |
| NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcinoma NT-I7, Nivolumab - Gastric or Gastro-esophageal Junction (GEJ) or Esophageal Adenocarcinoma (EAC) | Phase 1 | Terminated | NeoImmuneTech | 10 | 2021-01-21 | 2024-08-16 |
| A Trial of NT-I7 in COVID-19 (SPESELPIS) Double-Blind NT-I7, Double-Blind Placebo - COVID-19 | Phase 1 | Terminated | NeoImmuneTech | 7 | 2020-11-27 | 2023-07-14 |
| NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors NT-I7, pembrolizumab (KEYTRUDA®) - Any Advanced Solid Tumors, Triple Negative Breast Cancer | Phase 1 / Phase 2 | Completed | NeoImmuneTech | 215 | 2020-06-10 | 2026-03-09 |
| High-Risk Skin Cancers With Atezolizumab Plus NT-I7 NT-I7, atezolizumab - Melanoma, Merkel Cell Carcinoma | Phase 1 / Phase 2 | Terminated | NeoImmuneTech | 31 | 2019-12-26 | 2025-10-22 |
| rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temozolomide rhIL-7-hyFc, Placebo, Temozolomide - Glioma | Phase 1 / Phase 2 | Active not recruiting | Washington University School of Medicine | 42 | 2019-01-04 | 2025-11-25 |
| Study of the Effect NT-I7 on CD4 Counts in Patients With High Grade Gliomas Laboratory Biomarker Analysis, NT-I7, Placebo - Lymphopenia, Malignant Glioma | Phase 1 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 12 | 2018-10-30 | 2023-10-06 |
| Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity Docetaxel, Carboplatin, FDG-PET/MR - Triple Negative Breast Neoplasms | Phase 2 | Terminated | Washington University School of Medicine | 148 | 2014-07-07 | 2022-11-07 |
COVID-19 (2) · Carcinoma, Non-Small-Cell Lung (2) · Glioma (2) · Neoplasm Metastasis (2) · Squamous Cell Carcinoma of Head and Neck (2) · Triple Negative Breast Neoplasms (2) · Breast Neoplasms (1) · Carcinoma (1) · Carcinoma, Merkel Cell (1) · Colorectal Neoplasms (1) · Glioblastoma (1) · Gliosarcoma (1) · Leukoencephalopathy, Progressive Multifocal (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Non-Hodgkin (1)
efineptakin alfa (16) · pembrolizumab (3) · atezolizumab (2) · axicabtagene ciloleucel (2) · gosha-jinki-gan (2) · Biopsy (1) · Blood Specimen Collection (1) · Carboplatin (1) · Docetaxel (1) · Immunotherapy, Adoptive (1) · Nivolumab (1) · Radiotherapy (1) · Specimen Handling (1) · Temozolomide (1) · tisagenlecleucel (1)
United States (16) · Poland (1) · South Korea (1)
Andrea Lisco, M.D. (1) · Brian Gastman, MD (1) · Donghoon Choi, PhD (1) · Foluso Ademuyiwa, M.D., MPH (1) · Hye Ryun Kim (1) · Hyunseok Kang, MD (1) · Irene CM Cortese, M.D. (1) · Jian Campian, M.D., Ph.D. (1) · Jian L Campian, MD, PhD (1) · Jian L. Campian, MD, PhD (1) · John DiPersio, M.D. (1) · Martin Cheever, MD (1) · Michael Slade, M.D., M.S.C.I (1) · Milan Chheda, M.D. (1) · Mustafa A Hyder, M.D. (1)
R01CA286488 (1), R01CA288862 (1), U24CA209837 (1), UM1CA137443 (1)